Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 455

1.

Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.

Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG.

Recent Results Cancer Res. 2003;164:273-88.

PMID:
12899529
2.

The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.

Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.

Clin Cancer Res. 2000 Mar;6(3):901-8.

3.

Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.

Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.

Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):241-8.

4.

Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.

Skowronski RJ, Peehl DM, Feldman D.

Endocrinology. 1995 Jan;136(1):20-6.

PMID:
7530193
5.

19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.

Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler HP.

Cancer Res. 1998 Aug 1;58(15):3370-5.

6.

Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.

Akutsu N, Lin R, Bastien Y, Bestawros A, Enepekides DJ, Black MJ, White JH.

Mol Endocrinol. 2001 Jul;15(7):1127-39.

PMID:
11435613
7.
8.

20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.

Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.

Anticancer Res. 1999 May-Jun;19(3A):1689-97.

PMID:
10470102
9.

Action of low calcemic 1alpha,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma.

Prudencio J, Akutsu N, Benlimame N, Wang T, Bastien Y, Lin R, Black MJ, Alaoui-Jamali MA, White JH.

J Natl Cancer Inst. 2001 May 16;93(10):745-53.

PMID:
11353784
10.

25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.

Barreto AM, Schwartz GG, Woodruff R, Cramer SD.

Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):265-70.

12.

Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer.

Flanagan JN, Zheng S, Chiang KC, Kittaka A, Sakaki T, Nakabayashi S, Zhao X, Spanjaard RA, Persons KS, Mathieu JS, Holick MF, Chen TC.

Anticancer Res. 2009 Sep;29(9):3547-53. Erratum in: Anticancer Res. 2010 Mar;30(3):1033. Anticancer Res. 2010 Jan;30(1):277.

13.

Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.

Banwell CM, Singh R, Stewart PM, Uskokovic MR, Campbell MJ.

Recent Results Cancer Res. 2003;164:83-98.

PMID:
12899515
14.
16.

Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia.

Yu J, Papavasiliou V, Rhim J, Goltzman D, Kremer R.

Anticancer Drugs. 1995 Feb;6(1):101-8.

PMID:
7756673
17.

Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.

Mehta RG, Moriarty RM, Mehta RR, Penmasta R, Lazzaro G, Constantinou A, Guo L.

J Natl Cancer Inst. 1997 Feb 5;89(3):212-8.

PMID:
9017001
18.

Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression.

Sasaki H, Harada H, Handa Y, Morino H, Suzawa M, Shimpo E, Katsumata T, Masuhiro Y, Matsuda K, Ebihara K, et al.

Biochemistry. 1995 Jan 10;34(1):370-7.

PMID:
7819220
19.

Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines.

de Vos S, Holden S, Heber D, Elstner E, Binderup L, Uskokovic M, Rude B, Chen DL, Le J, Cho SK, Koeffler HP.

Prostate. 1997 May 1;31(2):77-83.

PMID:
9140119
20.

Supplemental Content

Support Center